What Lofox Treats: Main Uses and Benefits

Lofox (Lomefloxacin) is a therapeutic agent that is commonly used to help manage bacterial infections across several key organ systems. It is applied across domains where additional symptomatic support is needed. Its application is aligned with recognized therapeutic areas.

The medication is relevant in clinical settings for conditions characterized by periods of heightened symptoms, including bacterial infections of the urinary tract (both uncomplicated and complicated presentations), acute exacerbations of chronic bronchitis, and specific enteric infections. It is also used in a preventative capacity for infection prophylaxis before certain transurethral surgical procedures.

In these contexts, Lofox helps address symptom clusters that may become intense or disruptive, such as symptoms related to physical discomfort like painful urination and cough, systemic imbalance like fever, and increased urgency. Applied during phases of increased distress, it provides support that helps ease the overall symptom burden and assists with maintaining functional stability.

---

Quick Fact: Relief for Disruptive Symptoms
Primary Symptom Focus	Symptoms related to physical discomfort such as painful urination and cough, and systemic imbalance like fever.
Therapeutic Benefit	Provides support that helps ease the overall symptom burden.

---

Lofox is strictly limited to adult patients (18 years and older), as defined by regulatory documents. Use is contraindicated and explicitly prohibited in two primary groups: patients with a history of hypersensitivity or serious allergic reactions to lomefloxacin or any other quinolone antibiotic, and patients with a history of tendon disorder associated with prior quinolone use.

The medicine is not recommended in children and adolescents under 18 years of age, primarily due to the class-wide risk of irreversible damage to joint cartilage (arthropathy).

Eligibility for adults can be conditional on other factors. Patients with renal impairment (Creatinine Clearance leq 40 mL/min) require a mandated official dosage adjustment for continued use. Conversely, patients with hepatic impairment (cirrhosis) do not typically require a dose modification if renal function is adequate.

Use requires caution in older adults, patients receiving systemic corticosteroids, or those with an organ transplant due to an elevated risk of tendon damage. Use is also restricted during pregnancy (FDA Category C), and for lactation, a decision to discontinue nursing or discontinue the drug must be made.

Lofox Interactions with other medicines and products

Official regulatory documents define the interaction profile of Lofox (Lomefloxacin) based on both drug-drug and drug-product constraints, requiring specific management to maintain efficacy and safety.

Interacting Substances and Required Constraints

Interacting Entity	Interaction Type	Regulatory Constraint/Effect
Multivalent Cation-Containing Products (e.g., antacids, iron, zinc, calcium supplements, Sucralfate)	Absorption Reduction (Chelation)	Administration must be separated to mitigate the significant decrease in Lomefloxacin absorption and bioavailability.
Vitamin K Antagonists (e.g., Warfarin)	Pharmacodynamic Enhancement	Coagulation tests (e.g., PT/INR) must be monitored closely during concurrent use due to a documented risk of increased bleeding.
Theophylline, Fenbufen, and QTc-prolonging agents	Pharmacodynamic Risk	Use with caution is advised due to the potential for additive effects that may lower the seizure threshold or increase the risk of QTc prolongation.
Food	Absorption Alteration	Decreases the extent and delays the rate of Lomefloxacin absorption, resulting in a documented reduction of peak plasma concentration (C max) and total exposure (AUC).

Population-Specific Notes

The official labeling notes that Lomefloxacin clearance is reduced in elderly patients, leading to an increase in systemic drug exposure in this population. Conversely, in patients with confirmed cirrhosis (hepatic impairment), nonrenal clearance does not appear to be significantly reduced, and exposure is unchanged after a single dose.

Molecular Mechanism: Targeting Bacterial DNA Enzymes

Lomefloxacin's primary function is to act as a structural inhibitor against two crucial microbial enzymes: DNA Gyrase and Topoisomerase IV. These enzymes are vital for untangling and supercoiling the bacterial genome during replication and transcription. By forming a stable complex with the enzymes and the DNA, the drug effectively locks them in a non-functional state.

---

Mechanistic Cascade: Inducing Lethal Genomic Damage

The physical blockade of the DNA enzymes prevents the resealing of DNA strands that were transiently cut during the normal enzyme cycle. This action causes an accumulation of irreversible double-strand DNA breaks, which halts all core microbial genomic processes. This overwhelming genomic damage initiates a rapid and decisive bactericidal effect, resulting in the active killing of susceptible microbial pathogens.

---

Mechanism Limitations: Target Modification and Efflux

The mechanism is biologically constrained by the evolution of bacterial countermeasures. Mutations in the genes encoding the target enzymes (gyrA, parC) can reduce the drug's binding affinity, functionally weakening the inhibition. Furthermore, the overexpression of bacterial efflux pumps can actively expel Lomefloxacin from the cell, preventing it from reaching the necessary concentration to engage its targets.

Lofox (lomefloxacin) is an anti-infective agent intended for oral administration as a 400 mg film-coated tablet for systemic use. The standard usage pattern requires the tablet to be administered once daily. While the medication may be taken without regard to food, standard instructions emphasize that the tablet must be swallowed with a full glass of water (e.g., 8 ounces), and patients should maintain sufficient daily fluid intake throughout the treatment course.

The duration of the regimen is strictly defined by protocol. Courses can range from a single 400 mg dose administered 2 to 6 hours before certain surgical procedures (prophylaxis) to a full 14-day course for complicated bacterial infections. Other typical courses include 10 days for acute exacerbations of chronic bronchitis and 3 days for specific uncomplicated presentations.

A key administration principle involves the necessary timing separation from polyvalent cations. Products containing iron, aluminum, or magnesium, such as some supplements and antacids, must be avoided for a specific period (typically 4 hours before or 8 hours after the dose) to ensure the drug's proper action. Dosage adjustment is also necessary for adults with impaired renal function; in such cases, the initial 400 mg dose is followed by a maintenance dose of 200 mg once daily.

Research Evidence / Overview of Studies for Lofox

The available research on Lofox (Lomefloxacin) describes the structure and findings observed in clinical studies. This summary is intended to provide context on the evidence landscape and focuses only on what types of research have been conducted and the patterns that studies monitored, without offering any clinical advice or making claims about individual outcomes. Findings describe group patterns, and research provides context but not individual predictions.

---

Evidence for Use in Complicated Urinary Tract Infections (UTIs)

Initial research included Randomized Controlled Trials (RCTs) and multicenter studies that explored how symptoms change over time in adult patients with complicated UTIs. The studies monitored the Microbiological response (the presence or absence of the infectious bacteria) and the Clinical response (how symptoms evolved in the observed populations). Findings describe patterns observed in the studies related to the reduction in the presence of the causative organism when compared to other antibiotic regimens used in the research context. However, long-term outcomes are not consistently characterized across all available evidence.

---

Evidence for Use in Acute Exacerbation of Chronic Bronchitis

Studies explored the use of lomefloxacin in adults experiencing an acute worsening of their chronic bronchitis using Comparative Trials. Researchers monitored Symptom measures and Clinical outcomes, and the physician’s final assessment was used to categorize outcomes. Studies report how symptoms evolved in the observed populations, detailing measurements of success rates based on the overall clinical assessment in the short-term. The durability of clinical outcomes over a period exceeding one month following treatment is not a primary focus of the available trials, meaning long-term effects are not fully established.

---

Areas of Research Uncertainty and Study Limitations

The available research provides insight into short-term changes, but the long-term effects are not fully established, and certainty remains low regarding the very long-term prognosis after treatment. Comparative evidence is lacking for studies that directly assess lomefloxacin against many of the newest antibiotic agents currently available. Additionally, data for certain groups remain insufficient for detailed subgroup analysis, and findings are uncertain for populations that were typically excluded from the main efficacy trials, such as pediatric or severely immunocompromised patients.

Common questions about Lofox (FAQ)

---

Q: What is the main reason doctors prescribe Lofox?

Official regulatory documents indicate that Lofox is used to treat various bacterial infections, including specific types of urinary tract infections (UTIs), bronchitis, and prostatitis. It is also indicated for the prevention of UTIs before certain surgical procedures (known as prophylaxis).

Q: Is it normal to feel [general, non-clinical symptom like 'tired'] when starting Lofox?

The official product label documents common adverse effects on the central nervous system (CNS), such as headache and dizziness. While the label does not explicitly list fatigue or tiredness, the official label documents the presence of known CNS-related effects for this medication.

Q: Can Lofox be taken with common over-the-counter pain relievers?

Regulatory documents advise caution regarding the potential for drug interactions, specifically noting that use with certain nonsteroidal anti-inflammatory drugs (NSAIDs), such as Fenbufen, may increase the potential for central nervous system effects. Official information describes potential interactions that may require discussion with a healthcare provider regarding specific pain relievers.

Q: How does Lofox affect sleep patterns?

Official information lists adverse central nervous system effects, including confusion and the potential for seizures. While the label does not commonly list sleep disorders or insomnia, these neurological effects may indirectly influence a patient's sleep quality.

Q: Is Lofox approved for use in older adults?

The medication is permitted for use in older adults, though official safety information notes an increased risk for serious side effects, specifically severe tendon disorders, in this population. This risk is further heightened in older adults also taking systemic corticosteroids.

Q: What are the main things to avoid while taking Lofox?

Official constraints include avoiding products containing multivalent cations (such as iron, aluminum, or magnesium found in some supplements and antacids) for a specific time around the dose, as this can significantly reduce drug absorption. Regulatory documents describe that exercise or physical activity should be discontinued at the first sign of tendon pain or inflammation, due to the documented risk of tendon disorders.

Q: How long does Lofox stay in the system after the last dose?

The time the drug remains in the system is related to kidney function, which is assessed by creatinine clearance. For individuals with severely impaired renal function (kidney issues), the mean half-life (the time it takes for half the drug to be eliminated) can be increased to approximately 45 hours.

Q: Does the effectiveness of Lofox change over time?

Official microbiology data indicates that bacterial resistance to lomefloxacin develops slowly in laboratory testing through a multiple-step mutation process. This process of resistance development is one biological factor that can affect the long-term effectiveness of the drug.

Q: Can Lofox be taken in the evening?

Regulatory dosing instructions specify that the medication should be taken once a day. This once-daily schedule allows for flexibility in timing (morning or evening), provided the necessary separation from interacting products is maintained.

Q: What are the most common reasons Lofox might not work for someone?

Official documents related to the drug's mechanism cite potential mechanisms for reduced effectiveness. These include the development of bacterial resistance through gene mutation, and laboratory studies indicating the drug's activity may be slightly less potent at an acidic pH.

Q: Is there an official patient information leaflet for Lofox I can read?

The official product label confirms that patient counseling information and a specific document known as a Medication Guide are available for the product to help provide important drug facts.

Q: Can a person take Lofox if they have a history of liver issues?

According to official dosage guidelines, no adjustment to the dose is typically needed for adults with liver impairment (hepatic impairment), provided their kidney function is adequate.

Q: Is it true that Lofox has been studied in pediatric populations?

The medication is not approved for use in the pediatric population (those under 18 years of age). This restriction is due to regulatory concerns regarding the class-wide risk of irreversible damage to joint cartilage (arthropathy) in growing individuals.

Q: What kind of monitoring is recommended when taking Lofox (e.g., blood tests)?

Monitoring of drug levels is officially suggested for patients with impaired renal function (kidney issues). This monitoring helps to determine if the dosage interval needs to be adjusted.

Q: Do lifestyle factors, like diet or exercise, influence the effects of Lofox?

Official administration instructions state the dose may be taken without regard to meals (diet). Official information states that exercise should be avoided at the first sign of tendon pain, inflammation, or swelling, due to the documented risk of tendon disorders.

Q: What makes Lofox different from older treatments for the same condition?

Official classification documents describe Lofox as a difluoroquinolone, meaning it belongs to the second generation of the fluoroquinolone class of antibiotics. This classification indicates its place within a group of synthetic, broad-spectrum antimicrobial agents.

Q: If I have a mild reaction, what should I do?

Official instructions state that if symptoms of certain serious adverse reactions, such as peripheral neuropathy (nerve damage causing pain or tingling) or tendon pain/swelling, are experienced, the treatment regimen should be discontinued, and the physician contacted immediately for guidance.

Q: Is Lofox known by any other names?

The active ingredient is Lomefloxacin hydrochloride. The product has also been marketed under other official trade names, including Maxaquin and Uniquin.

Q: What are the documented safety classifications or categories for Lofox?

The product's official safety information includes a Boxed Warning regarding the risk of serious side effects, such as tendon rupture and peripheral neuropathy. The active ingredient itself is also categorized under certain global hazard systems as having Acute Oral Toxicity.

Q: Why are there different strengths of Lofox available?

While the standard dose is 400 mg, a lower 200 mg dose is required for maintenance therapy in adults with impaired renal function (kidney issues). The different strengths exist to accommodate these necessary dosage adjustments based on a patient's kidney function.

Q: Does Lofox require a special prescription or monitoring?

Lofox is a prescription-only medication. Monitoring of drug levels is officially suggested for patients with impaired renal function to guide necessary dose interval adjustments.

Storage Requirements

Official regulatory documents require that Lofox (Lomefloxacin hydrochloride tablets) be stored at Controlled Room Temperature. The medication must be protected from both excessive heat and moisture to ensure the stability of the film-coated tablets. The product must be kept in its original container.

Storage Restriction	Requirement
Temperature	Controlled Room Temperature
Protection	Guard against excessive heat and moisture
Child Safety	Keep out of the sight and reach of children and pets

Disposal Instructions

Expired or unused Lofox must be disposed of according to official regulatory guidelines. The preferred method is to use a drug take-back program or mail-back envelope. If a take-back program is not available, the medicine must be removed from its container, mixed with an undesirable substance (e.g., dirt, coffee grounds), placed in a sealed bag, and discarded in the household trash. Lofox is not on the FDA's list of medicines recommended for flushing.